Financial Performance - The company incurred net losses of approximately $288.7 million, $279.7 million, and $268.8 million for the fiscal years ended April 30, 2025, 2024, and 2023 respectively, resulting in an accumulated deficit of $1.4 billion as of April 30, 2025[174]. - The company expects to continue incurring net losses for the foreseeable future due to substantial investments in customer acquisition and software development[174]. - Increased compliance costs and operational expenses may negatively affect future results if revenue does not increase sufficiently[175]. - Revenue metrics such as net dollar-based retention rate may not accurately indicate future financial results due to dependence on a small number of high-value customer contracts[196]. - A decline in new or renewed subscriptions may have a small immediate impact but will negatively affect future revenue[229]. - The company may require additional financing in the future, which could lead to substantial dilution for existing stockholders if equity is sold[266]. - The company has limited experience in acquisitions and may face challenges in finding suitable candidates or integrating acquired businesses effectively[267]. Revenue and Customer Dynamics - Revenue growth may be adversely impacted by factors such as reduced demand for C3 AI Software, increased competition, and the inability to accurately forecast demand[176]. - A limited number of customers have historically accounted for a substantial portion of revenue, and if these customers do not renew contracts, revenue could decline[177]. - The average total subscription contract value is decreasing as the company expands its customer base beyond a small number of large customers[177]. - Future success depends on the ability to sell additional subscriptions to existing customers and ensure their renewal upon contract expiration[181]. - The company intends to grow its customer base by introducing product offerings with a lower entry price point, but faces risks associated with supporting smaller customers[182]. - The company derives substantially all of its revenue from subscriptions to C3 AI Software and Center of Excellence support services, making market acceptance critical for continued success[184]. - Future revenue growth depends on the ability to establish and maintain successful strategic partner relationships, which requires significant time and resources[202]. Competition and Market Risks - The company faces intense competition from various sources, including larger competitors with broader offerings and innovative startups[187]. - Changes in subscription or pricing models may adversely affect operating results, especially as new competitors enter the market[197]. - The introduction of new AI platforms by competitors could render C3 AI Software obsolete, adversely affecting business and financial condition[210]. - The market for C3 AI Software may not grow as expected, impacting business and financial condition if businesses fail to adopt the software[205]. Operational Challenges - The sales cycles for C3 AI Software can be long and unpredictable, particularly for large subscriptions, which may extend over several years[194]. - Individual large sales can represent a significant portion of overall sales, impacting cash flow and margins, making it difficult to project revenue accurately[195]. - Rapid growth since 2009 has placed significant strain on management and operational resources, which may affect future growth planning[217]. - Recruiting and training qualified sales representatives is resource-intensive, and delays in this process could hinder sales operations[213]. - Marketing and sales efforts must generate significant revenue increases; otherwise, sales growth may be slower than anticipated[214]. Compliance and Regulatory Risks - Compliance with evolving data privacy laws, such as GDPR and CCPA, imposes significant obligations and potential fines for noncompliance[236][240]. - The inability to lawfully transfer personal data across borders may lead to operational disruptions and increased regulatory scrutiny[238]. - The company faces increased compliance costs and potential liabilities due to stringent data protection laws in various jurisdictions[239]. - Future changes in data privacy regulations may require significant adaptations in business practices and contractual arrangements[239]. - The EU AI Act, effective from August 1, 2024, could impose fines of up to €35 million or 7% of the company's total worldwide annual turnover for non-compliance[241]. Cybersecurity and Data Protection - Cybersecurity threats, including ransomware and denial-of-service attacks, are increasing and could disrupt business operations and lead to reputational harm[245]. - The costs associated with responding to a security breach could be significant, potentially leading to unexpected interruptions and negative publicity[248]. - The company may face increased compliance burdens and costs due to rapidly evolving laws and regulations regarding data privacy and security[248]. - The company’s C3 AI Software processes sensitive data, and any security incidents could result in significant legal and financial consequences[244]. Intellectual Property and Legal Risks - The company holds a patent portfolio with 35 issued patents in the U.S. and over 60 pending applications, indicating a strong focus on intellectual property protection[297]. - The company may incur substantial indemnity payments due to intellectual property infringement claims, which could harm its financial results[296]. - The company faces potential legal risks related to the use of third-party open source software, which could lead to significant legal expenses and damages[298]. - The enforceability of the Apache License, Version 2.0, under which components of the C3 AI Software are provided, could negatively impact the company's software development and licensing model[302]. Market and Stock Performance - The trading price of the company's Class A common stock has been volatile, influenced by various factors including market fluctuations and sales by stockholders[304]. - The dual class structure of the company's common stock concentrates voting control with Class B stockholders, limiting the influence of Class A stockholders on corporate matters[309]. - Substantial future sales of Class A and Class B common stock could depress the market price of Class A common stock[312]. - The company may not be included in certain stock indices due to its dual class capital structure, potentially affecting its attractiveness to investors[311]. Foreign Operations and Currency Risks - The company is exposed to risks associated with fluctuations in foreign currency exchange rates as it expands international operations[258]. - 6% of revenue for the fiscal years ended April 30, 2025 and 2024 were denominated in currencies other than U.S. dollars[258]. - 7% of expenses for the fiscal years ended April 30, 2025 and 2024 were denominated in currencies other than U.S. dollars[258]. - A hypothetical 10% change in foreign currency exchange rates may result in a material impact on consolidated financial statements[465]. Miscellaneous Risks - Legal proceedings may arise that could negatively impact the company's business and financial condition[328]. - Catastrophic events could disrupt the company's operations, particularly given its location in a seismically active region[329]. - The company is subject to significant legal, accounting, and compliance costs as a public company, which may impact its financial condition[321].

Exhibit 99.1 We recently completed a debt financing, strengthening our liquidity. The Company expects Debt (2) as of June 30, 2025 will be $283 million, consisting of the $75 million in new borrowings described above and $208 million consisting solely of the principal amount of the Company's 2019 convertible notes. If all holders of the 2019 convertible notes execute their repurchase option for cash on July 1, 2025, the required repayment to noteholders would include an additional $20 million, for a total o ...

Table of Contents | UNITED STATES | | | --- | --- | | SECURITIES AND EXCHANGE COMMISSION | | | Washington, D.C. 20549 | | | FORM 10-Q | | | (MARK ONE) | | | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF | | | 1934 | | | For the quarterly period ended March 31, 2025 | | | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF | | | 1934 | | | For the transition period from | to | | Commission File Number: 001-42636 | | | EGH ACQUISITION CO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ☒ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from January 1, 2025 to March 31, 2025 Commission file number: 811-24071 Ellington Credit Company (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporatio ...

Midlothian, TX. June 23, 2025 -- Ennis, Inc. (the "Company"), (NYSE: EBF), today reported financial results for the first quarter ended May 31, 2025. Highlights include: Exhibit 99.1 FOR IMMEDIATE RELEASE ENNIS, INC. REPORTS RESULTS FOR THE QUARTER ENDED MAY 31, 2025 AND DECLARES QUARTERLY DIVIDEND Financial Overview The Company's revenues for the first quarter ended May 31, 2025 were $97.2 million compared to $103.1 million for the same quarter last year, a decrease of $5.9 million, or 5.7%. Gross profits ...

Table of Contents Commission File Number 001-34700 CASEY'S GENERAL STORES, INC. (Exact name of registrant as specified in its charter) United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended April 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (State or other jurisdiction of incorporation or organization) Iowa 42-09 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 1-15270 Nomura Horudingusu Kabushiki Kaisha (Exact name of registrant as specified in its charter) Nomura Holdings, Inc. (Translation of registrant's name into English) 13-1, Nihonbashi 1-chome Chuo-ku, Tokyo 103-8645 Japan (Jurisdiction of incorporation or organization) (Address of princ ...

Exhibit 99.1 Jerash Holdings Reports Financial Results for Fiscal 2025 Fourth Quarter and Full Year -- Record annual revenue of $145.8 million, up 24.4 percent from prior year -- Fiscal Fourth Quarter Highlights FAIRFIELD, N.J., June 23, 2025 – Jerash Holdings (US), Inc. (NASDAQ: JRSH) (the "Company" or "Jerash"), which manufactures and exports custom, ready-made, sportswear and outerwear for leading global brands, today announced financial results for its fiscal 2025 fourth quarter and full year ended Marc ...

Exhibit 99.1 Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipin ...

Exhibit 99.1 Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipin ...